Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.
about
Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.Assessing functional performance in the mdx mouse modelThe effects of low levels of dystrophin on mouse muscle function and pathologyEngraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal musclePoloxamer [corrected] 188 has a deleterious effect on dystrophic skeletal muscle function.Adaptive strength gains in dystrophic muscle exposed to repeated bouts of eccentric contractionSoluble miniagrin enhances contractile function of engineered skeletal muscle.How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouseMusculoskeletal Geometry, Muscle Architecture and Functional Specialisations of the Mouse HindlimbA prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.Elusive sources of variability of dystrophin rescue by exon skippingAutologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice.Opportunities and challenges for the development of antisense treatment in neuromuscular disorders.What do mouse models of muscular dystrophy tell us about the DAPC and its components?Viral Vector-Mediated Antisense Therapy for Genetic Diseases.Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2FNeuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts.The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy.Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.A Modified Wire Hanging Apparatus for Small Animal Muscle Function TestingAntisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD)Prosurvival Factors Improve Functional Engraftment of Myogenically Converted Dermal Cells into Dystrophic Skeletal Muscle.Use of vivo-morpholinos for control of protein expression in the adult rat brainRyanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples.A Dynamic Simulation of Musculoskeletal Function in the Mouse Hindlimb During Trotting Locomotion.Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
P2860
Q34041966-E9C850BE-5862-41E6-99FF-4E14D38D9D5CQ34153862-0A9A792F-884B-49E3-B933-F354A5A44E39Q34168463-06217C13-09A5-4978-8F70-FB7FE39464B1Q34794545-FA4D5027-3A00-450A-B00E-336640C02F00Q35123905-A8335D42-4F56-4FF7-9E0C-0B541E98E0F7Q35601682-BAB10BD6-ADCD-4A3C-84C6-BA52623B31DEQ35790235-BB193E09-8BD4-494A-BC2F-2E8867D07FF0Q35821127-7D4157CA-1DC5-4C5F-BD30-DAAB62F1D966Q35999318-590A0ACD-665E-4C12-95F4-FB7F81B69F74Q36114216-5AD59F6E-1659-4DCE-A823-C22513CA9895Q36340978-B4EACF3B-6484-4DFB-88C8-6C9D643CCBADQ36506919-8D47F46D-3E1E-40F7-B64E-CFED007ACBF0Q37510390-1D29D9B1-0681-4BCF-A621-71E46BFF9683Q37718154-91DEA030-B233-4EBB-993E-975BC2C9866FQ37867701-A39078D2-A779-4DDD-A28F-ACBFF60C8BEBQ38255744-8CE1A0C1-4C24-4E56-A921-ACCC139559C6Q38289261-43021269-7F34-4B7C-962B-3EC7BF0BBC99Q38630255-FF911CA2-3BE7-4B5C-9D8C-9FF910A3FE48Q38658555-3B16FCEA-2986-4D33-BBE6-DB6FA803DEA2Q39314908-8E271170-D974-4464-B5D4-B914CD4421A1Q40219200-70B933DA-EB99-4C3C-8E09-6930816E0CC0Q40445952-75816B09-1920-4C08-98C1-B4E92357F01FQ40603890-96C9A79B-55AF-4926-B084-B7802E71A950Q40956001-CD6BAD93-0756-4347-811F-F8878B2EC23EQ42036512-18B8E4A5-93FA-46F5-BA88-0AC452968BE0Q42122236-5EB7F79B-DA34-44D6-A7C9-6572C6748624Q42391300-C0C3313D-2294-4546-AE7D-3131B71E50E9Q42827488-7ADC9B08-D16C-43D5-AE43-F4EFCEC32B29Q47665947-578D50B3-1A32-4AC7-B06A-EC15CF5BE550Q48097715-0AE8119D-4DB9-493B-B223-994E30271AAEQ48300126-279F4A9C-F023-463E-837E-18EA835CAB22Q50243875-3F277FCE-6195-475D-B82C-04980F9C8EC2Q52631121-AD1C8FF9-8EA7-41DF-BF24-BA0BE90852B2Q55129533-09AB6CCA-CFEC-4800-AA89-18571A8FD097Q55309190-B1F7F188-76DC-46DD-A7EE-41A45E7B6D1CQ57039821-8F16E960-6452-4477-BBDF-A77B1560EBD2
P2860
Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Physiological characterization ...... owing local antisense therapy.
@ast
Physiological characterization ...... owing local antisense therapy.
@en
Physiological characterization ...... owing local antisense therapy.
@nl
type
label
Physiological characterization ...... owing local antisense therapy.
@ast
Physiological characterization ...... owing local antisense therapy.
@en
Physiological characterization ...... owing local antisense therapy.
@nl
prefLabel
Physiological characterization ...... owing local antisense therapy.
@ast
Physiological characterization ...... owing local antisense therapy.
@en
Physiological characterization ...... owing local antisense therapy.
@nl
P2860
P356
P1433
P1476
Physiological characterization ...... lowing local antisense therapy
@en
P2093
Paul S Sharp
P2860
P304
P356
10.1038/MT.2010.213
P577
2010-10-05T00:00:00Z